ascopubs.org

Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology, US Food and Drug Administration Public Workshop—Workshop Proceedings

Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma Next-generation sequencing ...
Healio

Findings allow for better risk assessment and personalized treatment for BRCA2 carriers

Please provide your email address to receive an email when new articles are posted on . Researchers assigned clinical classifications to thousands of BRCA2 variants of uncertain significance. Research ...
Business Wire

Invitae Presents New Data Demonstrating High Concordance of Variant Classifications for BRCA1/2 Across Major Clinical Testing Laboratories

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today presented an important study at the 2016 American College of Medical Genetics and Genomics (ACMG) ...
Nasdaq

Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification

SAN FRANCISCO, March 12, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced the launch of an update to Invitae Generation™ with Clinical Variant Modeling, a ...
technologynetworks

OGT and QIAGEN Announce Partnership That Unlocks a Complete Sample To Report Workflow for SureSeq NGS Panels

The partnership between OGT and QIAGEN Digital Insights (QDI), expands OGT’s bioinformatics capabilities by integrating QIAGEN’s advanced tertiary analysis solution, QCI Interpret, with its SureSeq™ ...